Skip to Main content Skip to Navigation
Journal articles

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

Stanislas Pol 1, * Marc Bourlière 2, 3 Sandy Lucier 4, 5 Christophe Hézode 6 Céline Dorival 5 Dominique Larrey 7, 8 Jean-Pierre Bronowicki 9, 10 Victor D. E. Ledinghen 11 Fabien Zoulim 12 Albert Tran 13 Sophie Metivier 14 Jean-Pierre Zarski 15, 16 Didier Samuel 17, 18 Dominique Guyader 19 Patrick Marcellin 20 Anne Minello 21, 22 Laurent Alric 23 Dominique Thabut 24, 25 Olivier Chazouillères 26, 25 Ghassan Riachi 27 Valérie Bourcier 28 Philippe Mathurin 29 Véronique Loustaud-Ratti 30, 31 Louis D’alteroche 32 Isabelle Fouchard-Hubert 33, 34 François Habersetzer 35 Xavier Causse 36 Claire Geist 37 Isabelle Rosa 38 Jérôme Gournay 39 Eric Saillard 40 Eric Billaud 41 Ventzislava Petrov-Sanchez 42 Alpha Diallo 42 Hélène Fontaine 1 Fabrice Carrat 5
* Corresponding author
Abstract : Background & aims - We report the first real-life results of the sofosbuvir+daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients. Methods - The France REcherche Nord&Sud Sida-hiv Hépatites (ANRS) CO22 HEPATHER "Therapeutic options for hepatitis B and C: A French cohort" is a multicentre observational cohort which aims to include 15,000 HCV- and 10,000 HBV-infected patients. We selected all participants (n=768) with a HCV genotype 1 who initiated sofosbuvir (400mg/day) and daclatasvir (60mg/day) before October 1st 2014, with or without ribavirin (1-1.2g/day) for a duration of 12weeks or 24weeks. The main endpoint criterion was sustained virological response at 12weeks (SVR12), defined by the absence of detectable HCV-RNA 12weeks after the last treatment intake. Missing SVR12 measurements were imputed using SVR24 measurements (n=45), otherwise considered as virological failure (n=18). Results - A SVR12 was obtained in 729/768 (95%) patients, ranging from 92% (12-week sofosbuvir+daclatasvir) to 99% (24-week sofosbuvir+daclatasvir+ribavirin). The SVR12 rates did not significantly differ between the 24-week (550/574 (96%)) and the 12-week (179/194 (92%); p=0.0688) durations or between regimens with (165/169 (98%)) or without ribavirin (564/599 (94%); p=0.0850). The SVR12 rate was greater than 97% in non-cirrhotic patients irrespective of the treatment duration or the addition of ribavirin. Among cirrhotic patients, the SVR12 rate was higher with 24 than 12-week regimen (423/444 (95%) vs. 105/119 (88%); p=0.0054). Conclusion - The sofosbuvir+daclatasvir combination is associated with a high rate of SVR12 in patients infected by genotype 1, with an optimal duration of 12weeks in non-cirrhotic and 24weeks in cirrhotic patients. The number of patients receiving ribavirin was too low to adequately assess its impact. Lay summary - The sofosbuvir+daclatasvir combination of antiviral drugs is associated with a high rate (95%) of viral eradication in patients infected by HCV genotype 1. The best duration of a ribavirin-free sofosbuvir+daclatasvir combination seems to be 12weeks in non-cirrhotic patients and 24weeks for those with cirrhosis. Clinical trial number: NCT01953458.
Complete list of metadata

Cited literature [18 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Wednesday, March 28, 2018 - 10:58:36 AM
Last modification on : Tuesday, November 16, 2021 - 4:13:19 AM
Long-term archiving on: : Thursday, September 13, 2018 - 9:52:12 AM



Stanislas Pol, Marc Bourlière, Sandy Lucier, Christophe Hézode, Céline Dorival, et al.. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of Hepatology, Elsevier, 2017, 66 (1), pp.39-47. ⟨10.1016/j.jhep.2016.08.021⟩. ⟨hal-01435007⟩



Record views


Files downloads